ANGLE plc (GB:AGL) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
ANGLE plc has unveiled promising research indicating that its Parsortix system can effectively capture circulating tumor cells (CTCs) in prostate cancer patients, potentially aiding the development of targeted therapies. This breakthrough could enhance patient stratification in clinical trials, improving outcomes by tailoring treatments to specific biomarkers. With 67% of localized and 77% of treated patients showing positive biomarkers, ANGLE’s technology could revolutionize cancer treatment strategies.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.